Cargando…

Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio

BACKGROUND: Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molfenter, Todd, Sherbeck, Carol, Zehner, Mark, Quanbeck, Andy, McCarty, Dennis, Kim, Jee-Seon, Starr, Sandy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395880/ https://www.ncbi.nlm.nih.gov/pubmed/25884206 http://dx.doi.org/10.1186/s13011-015-0009-2

Ejemplares similares

Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio
por: Molfenter, Todd, et al.
Publicado: (2018)

Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial
por: Molfenter, Todd, et al.
Publicado: (2013)

Physicians’ satisfaction with providing buprenorphine treatment
por: Knudsen, Hannah K., et al.
Publicado: (2019)

The readiness of addiction treatment agencies for health care reform
por: Molfenter, Todd, et al.
Publicado: (2012)

The pressing shortage of buprenorphine prescribers and the pending role of telemedicine
por: Molfenter, Todd
Publicado: (2015)

Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
por: Parran, Theodore V, et al.
Publicado: (2017)

A Descriptive Study on Opioid Misuse Prevalence and Office-Based Buprenorphine Access in Ohio Prior to the Removal of the Drug Addiction Treatment Act of 2000 Waiver
por: McKnight, Erin R, et al.
Publicado: (2023)

Making the business case for an addiction medicine consult service: a qualitative analysis
por: Priest, Kelsey C., et al.
Publicado: (2019)

Use of Telemedicine in Addiction Treatment: Current Practices and Organizational Implementation Characteristics
por: Molfenter, Todd, et al.
Publicado: (2018)

Trends in telemedicine use in addiction treatment
por: Molfenter, Todd, et al.
Publicado: (2015)

The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio
por: Brook, Daniel L, et al.
Publicado: (2021)

Using Stakeholder Values to Promote Implementation of an Evidence-Based Mobile Health Intervention for Addiction Treatment in Primary Care Settings
por: Quanbeck, Andrew
Publicado: (2019)

Tobacco Addiction and Smoking Status in Heroin Addicts under Methadone vs. Buprenorphine Therapy
por: Pajusco, Benedetta, et al.
Publicado: (2012)

1053. The Ecological Relationship Between County-Level HCV Case Rates and Office-Based Buprenorphine in Ohio
por: Brook, Daniel L, et al.
Publicado: (2020)

Management of opioid addiction with buprenorphine: French history and current management
por: Poloméni, Pierre, et al.
Publicado: (2014)

Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration
por: Manolis, Chronis H., et al.
Publicado: (2016)

Sepsis-2.5: Resolving Conflicts Between Payers and Providers
por: Rodenberg, Howard, et al.
Publicado: (2023)

Need for payer-provider partnerships in addressing social determinants of health
por: Kannarkat, Joseph T, et al.
Publicado: (2021)

Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020
por: Strahan, Andrea E., et al.
Publicado: (2023)

A Data-Driven Response to the Addiction Crisis in Hamilton County, Ohio
por: Manchak, Sarah M., et al.
Publicado: (2022)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Buprenorphine unobserved “home” induction: a survey of Ontario’s addiction physicians
por: Srivastava, Anita, et al.
Publicado: (2019)

Making the Case for Addressing Health Disparities: What Drives Providers and Payers?
por: Johnson, Margaret, et al.
Publicado: (2018)

Consolidation in the dental industry: a closer look at dental payers and providers
por: Nasseh, Kamyar, et al.
Publicado: (2019)

Variability in Private Payer Medical Policies for Osteochondral Allograft Transplantation Demonstrates the Absence of Standardization in Medical Criteria Between Payers
por: Tabbaa, Suzanne M., et al.
Publicado: (2022)

Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?
por: Maremmani, Angelo Giovanni Icro, et al.
Publicado: (2011)

Buprenorphine/naloxone addiction in a pharmacist as a result of migraine self-treatment
por: Norton, Merrill, et al.
Publicado: (2016)

New developments in managing opioid addiction: impact of a subdermal buprenorphine implant
por: Itzoe, MariaLisa, et al.
Publicado: (2017)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Hospitals and the Tax-Payer
Publicado: (1920)

Buprenorphine Waiver Attitudes Among Primary Care Providers
por: Lai, Benjamin, et al.
Publicado: (2022)

Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study
por: Johnson, Björn, et al.
Publicado: (2022)

Disseminating quality improvement: study protocol for a large cluster-randomized trial
por: Quanbeck, Andrew R, et al.
Publicado: (2011)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers
por: Lopata, Erin, et al.
Publicado: (2021)

A Private Payer Persective
por: Shurney, Dexter W.
Publicado: (2006)

Initial Validation and Findings From the Willing/Ready Subscale of the Church Addiction Response Scale
por: Clements, Andrea D., et al.
Publicado: (2021)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

Ohio
Publicado: (1896)

Ohio
Publicado: (1896)

Cannot write session to /tmp/vufind_sessions/sess_o37k90sde23dhf2hoa2dqvh1n1